[go: up one dir, main page]

ZA200406919B - Formoterol superfine formulation - Google Patents

Formoterol superfine formulation Download PDF

Info

Publication number
ZA200406919B
ZA200406919B ZA200406919A ZA200406919A ZA200406919B ZA 200406919 B ZA200406919 B ZA 200406919B ZA 200406919 A ZA200406919 A ZA 200406919A ZA 200406919 A ZA200406919 A ZA 200406919A ZA 200406919 B ZA200406919 B ZA 200406919B
Authority
ZA
South Africa
Prior art keywords
formulation according
pharmaceutical formulation
hfa
formoterol
propellant
Prior art date
Application number
ZA200406919A
Other languages
English (en)
Inventor
Rebecca Jaine Davies
David Ganderton
David Andrew Lewis
Brian John Meakin
Tanya Kathleen Church
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of ZA200406919B publication Critical patent/ZA200406919B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200406919A 2002-03-01 2004-08-31 Formoterol superfine formulation ZA200406919B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (de) 2002-03-01 2002-03-01 Aerosolformulierungen zur pulmonalen Verabreichung von Arzneimitteln mit systemischer Wirkung

Publications (1)

Publication Number Publication Date
ZA200406919B true ZA200406919B (en) 2006-06-28

Family

ID=27675679

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA200406918A ZA200406918B (en) 2002-03-01 2004-08-31 Pressurised metered dose inhalers containing solutions of beta-2 agonists
ZA200406919A ZA200406919B (en) 2002-03-01 2004-08-31 Formoterol superfine formulation
ZA200406917A ZA200406917B (en) 2002-03-01 2004-08-31 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200406918A ZA200406918B (en) 2002-03-01 2004-08-31 Pressurised metered dose inhalers containing solutions of beta-2 agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA200406917A ZA200406917B (en) 2002-03-01 2004-08-31 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect

Country Status (27)

Country Link
US (1) US20050129621A1 (de)
EP (2) EP1340492A1 (de)
JP (1) JP2005519094A (de)
KR (1) KR20040091050A (de)
CN (2) CN1638731A (de)
AR (2) AR038643A1 (de)
AT (1) ATE488224T1 (de)
AU (1) AU2003215597B2 (de)
BR (1) BR0303348A (de)
CA (1) CA2477879C (de)
DE (1) DE60334973D1 (de)
EA (1) EA008571B1 (de)
ES (1) ES2358293T3 (de)
GE (1) GEP20063985B (de)
HR (1) HRP20040751A2 (de)
IL (1) IL163842A0 (de)
MA (1) MA27107A1 (de)
MX (1) MXPA04008370A (de)
NO (1) NO20034874L (de)
NZ (1) NZ535019A (de)
PE (1) PE20030949A1 (de)
PL (1) PL372261A1 (de)
TN (1) TNSN04148A1 (de)
TW (1) TW200304833A (de)
UA (2) UA81238C2 (de)
WO (1) WO2003074023A1 (de)
ZA (3) ZA200406918B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
SI3494995T1 (sl) * 2002-03-01 2020-08-31 Chiesi Farmaceutici S.P.A. Superfina formulacija formoterola
EP1415647A1 (de) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
EP1452179A1 (de) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
WO2005025550A1 (en) * 2003-09-15 2005-03-24 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EA013428B1 (ru) * 2004-07-02 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх РАСПЫЛЯЕМЫЕ В ВИДЕ АЭРОЗОЛЯ СУСПЕНЗИОННЫЕ КОМПОЗИЦИИ С TG 227ea ИЛИ TG 134a В КАЧЕСТВЕ ПРОПЕЛЛЕНТА
RU2457832C2 (ru) * 2005-09-25 2012-08-10 Сипла Лимитед Состав на основе тровентола
US20070243262A1 (en) * 2005-12-21 2007-10-18 Hurley Kevin P Stable S-nitrosothiol formulations
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (de) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Aktuator für einen Inhalator für abgemessene Dosen
UY31235A1 (es) * 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2010074753A1 (en) * 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
ES2855159T3 (es) * 2010-07-12 2021-09-23 Xellia Pharmaceuticals Aps Tratamiento de las infecciones pulmonares mediante administración de tobramicina por aerolización
CA2811692C (en) 2010-09-22 2020-02-18 The Board Of Regents Of The University Of Texas System Novel block copolymer and micelle compositions and methods of use thereof
US8778383B2 (en) 2011-06-07 2014-07-15 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
CA2859209A1 (en) * 2011-12-20 2013-06-27 Map Pharmaceuticals, Inc. Excipient-free aerosol formulation
GB201402513D0 (en) * 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
EP3297710A4 (de) * 2015-05-21 2019-05-01 Island Breeze Systems Ca, LLC Treibmittelbasierter inhalator mit abgemessener dosis sowie lebensmittelapplikatoren und applikatoren
US11129848B2 (en) 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IES80485B2 (en) * 1996-12-04 1998-08-12 Bioglan Ireland R & D Ltd Pharmaceutical compositions and devices for their administration
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
GB2354007B (en) * 1999-09-11 2003-10-22 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
HU228237B1 (en) * 2000-03-09 2013-02-28 Gw Pharma Ltd Pharmaceutical compositions comprising cannabis and a pump spray device for the delivery of the compositions
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
UA73986C2 (uk) * 2000-05-22 2005-10-17 К'Єзі Фармачеутічі С.П.А. АЕРОЗОЛЬНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ <font face="Symbol">b</font>2-АДРЕНЕРГІЧНИЙ АГОНІСТ ТРИВАЛОЇ ДІЇ, ДОЗУЮЧИЙ ІНГАЛЯТОР ПІД ТИСКОМ ТА СПОСІБ ЙОГО ЗАПОВНЕННЯ
SI3494995T1 (sl) * 2002-03-01 2020-08-31 Chiesi Farmaceutici S.P.A. Superfina formulacija formoterola
EP1595531A1 (de) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren

Also Published As

Publication number Publication date
JP2005519094A (ja) 2005-06-30
GEP20063985B (en) 2006-12-11
EA200401006A1 (ru) 2005-04-28
US20050129621A1 (en) 2005-06-16
PE20030949A1 (es) 2004-01-02
NO20034874D0 (no) 2003-10-31
AU2003215597B2 (en) 2008-07-31
TNSN04148A1 (en) 2007-03-12
ZA200406918B (en) 2006-06-28
WO2003074023A1 (en) 2003-09-12
EP1480616B1 (de) 2010-11-17
KR20040091050A (ko) 2004-10-27
ES2358293T3 (es) 2011-05-09
ZA200406917B (en) 2006-06-28
ATE488224T1 (de) 2010-12-15
TW200304833A (en) 2003-10-16
AR101593A2 (es) 2016-12-28
NZ535019A (en) 2006-09-29
PL372261A1 (en) 2005-07-11
EP1340492A1 (de) 2003-09-03
MXPA04008370A (es) 2004-11-26
EP1480616A1 (de) 2004-12-01
DE60334973D1 (de) 2010-12-30
IL163842A0 (en) 2005-12-18
HRP20040751A2 (en) 2004-12-31
CN1638731A (zh) 2005-07-13
NO20034874L (no) 2003-12-23
EA008571B1 (ru) 2007-06-29
BR0303348A (pt) 2004-07-13
CN101502500A (zh) 2009-08-12
MA27107A1 (fr) 2004-12-20
UA80695C2 (en) 2007-10-25
UA81238C2 (en) 2007-12-25
AU2003215597A1 (en) 2003-09-16
CA2477879A1 (en) 2003-09-12
CA2477879C (en) 2011-05-03
AR038643A1 (es) 2005-01-19

Similar Documents

Publication Publication Date Title
AU2003222753B2 (en) Formoterol superfine formulation
ZA200406919B (en) Formoterol superfine formulation
CA2503183C (en) Salmeterol superfine formulation